Larimar Therapeutics Taps Veteran Biopharma Exec as COO Amid Key Drug Development Phase
Event summary
- John Harlow appointed President and COO of Larimar Therapeutics effective September 29, 2026.
- Harlow brings 25 years of commercial and operational experience from roles at Esperion Therapeutics, Melinta Therapeutics, and others.
- Inducement grant includes 800,000 stock options and 50,000 restricted stock units.
- Appointment coincides with the advancement of nomlabofusp toward potential approval for Friedreich's ataxia.
The big picture
Larimar's appointment of John Harlow as COO underscores its focus on strengthening commercial capabilities ahead of a potential nomlabofusp launch. The move reflects a broader trend in biotech where companies prioritize operational expertise to navigate complex regulatory and market dynamics. Harlow's track record in building high-performing commercial teams suggests Larimar is positioning itself for a competitive edge in the rare disease space.
What we're watching
- Commercialization Readiness
- How Harlow's experience will accelerate Larimar's preparedness for nomlabofusp's potential launch.
- Operational Scaling
- Whether Larimar can effectively scale its operations to support global commercialization efforts.
- Strategic Partnerships
- The pace at which Larimar forms new alliances to bolster its commercial infrastructure.
Related topics